Fairpointe Capital’s Kindred Biosciences, Inc. KIN Stock Holding History

Fairpointe Capital’s Portfolio KIN Stock Details KIN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-10,000	Closed	-$40K	–	77
2020 Q1	$40K	Hold	10,000	–	–	0.01%	75
2019 Q4	$85K	Hold	10,000	–	–	0.01%	75
2019 Q3	$68K	Hold	10,000	–	–	﹤0.01%	78
2019 Q2	$83K	Hold	10,000	–	–	﹤0.01%	78
2019 Q1	$92K	Hold	10,000	–	–	﹤0.01%	79
2018 Q4	$109K	Buy	+10,000	New	+$126K	﹤0.01%	82

Other funds holding KIN

PWAM

Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Fairpointe Capital's KIN Position: Q2 2020 in Review

Fairpointe Capital sold out of Kindred Biosciences, Inc. (KIN) in Q2 2020, closing a stake of 10,000 shares — an estimated $40K sold.

Fairpointe Capital first reported a position in KIN in Q4 2018 and held it in 6 quarters. The position peaked at $109K in Q4 2018. 83 funds tracked by Wall St. Rank hold KIN as of Q2 2020.

Fairpointe Capital reported no remaining Kindred Biosciences, Inc. position as of Q2 2020 after selling out during the quarter.
Fairpointe Capital sold 10,000 Kindred Biosciences, Inc. shares in Q2 2020, an estimated $40K.
Fairpointe Capital first reported a position in Kindred Biosciences, Inc. in Q4 2018 and held it in 6 quarters.
Fairpointe Capital's Kindred Biosciences, Inc. position peaked at $109K in Q4 2018.
83 funds tracked by Wall St. Rank held Kindred Biosciences, Inc. as of Q2 2020.

Based on Fairpointe Capital's 13F filing for Q2 2020, filed 14 Aug 2020.